Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Assay and Drug Development Technologies is Scopus-indexed (Q3, CiteScore 3.8), WoS SCIE. Published by SAGE Publications Ltd.
Checked against the index lists dated .
ISSN 1540-658XVerify ISSN ↗1557-8127Verify ISSN ↗
Publisher: SAGE Publications Ltd
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Drug Discovery | 99 / 161 | 38th | Q3 |
| Molecular Medicine | 127 / 179 | 29th | Q3 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2002–present, best quartile Q3, CiteScore 3.8.
Assay and Drug Development Technologies is Q3 in Drug Discovery (rank 99 of 161) and Q3 in Molecular Medicine (rank 127 of 179), by CiteScore 2025.
Assay and Drug Development Technologies is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 3.8, which places it in quartile Q3 at the 38th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.327, quartile Q3, with an H-index of 68.
Assay and Drug Development Technologies is published by SAGE Publications Ltd. Its print ISSN is 1540-658X and its online ISSN is 1557-8127.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Assay and Drug Development Technologies has an h-index of 73 and a 2-year mean of 2.55 citations per paper (OpenAlex). Its Scopus CiteScore is 3.8, quartile Q3. On 2-year citations it ranks #80 of 159 Scopus journals in Drug Discovery.
Assay and Drug Development Technologies published 40 papers in 2025; its busiest recent year was 2021 with 55. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 93 research articles (2023–2026), authors are most often from India (61.5%), China (15.1%) and United States (6.3%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.